FDG-PET Imaging in Pneumocystis carinii Pneumonia

Win, Zarni; Todd, Jonathan; Al-Nahhas, Adil

doi:10.1097/01.rlu.0000178784.58278.36

Cited by 29 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, in a clinical study, FDG uptake returned to normal levels after successful antifungal therapy for a lung abscess caused by candidal infection [48] and after therapy for Pneumocystis jiroveci pneumonia [49].…”

Section: Acute Infectious Processesmentioning

confidence: 99%

PET/CT in nononcological lung diseases: current applications and future perspectives

et al. 2016

View full text Add to dashboard Cite

Positron emission tomography (PET) combined with computed tomography (CT) is an established diagnostic modality that has become an essential imaging tool in oncological practice. However, thanks to its noninvasive nature and its capability to provide physiological information, the main applications of this technique have significantly expanded. 18F-labelled fluorodeoxyglucose (FDG) is the most commonly used radiopharmaceutical for PET scanning and demonstrates metabolic activity in various tissues. Since activated inflammatory cells, like malignant cells, predominantly metabolise glucose as a source of energy and increase expression of glucose transporters when activated, FDG-PET/CT can be successfully used to detect and monitor a variety of lung diseases, such as infections and several inflammatory conditions.The added value of FDG-PET/CT as a molecular imaging technique relies on its capability to identify disease in very early stages, long before the appearance of structural changes detectable by conventional imaging. Furthermore, by detecting the active phase of infectious or inflammatory processes, disease progression and treatment efficacy can be monitored. This review will focus on the clinical use of FDG-PET/CT in nonmalignant pulmonary diseases. @ERSpublications PET/CT is an imaging modality that could play a role in evaluation of inflammatory and infectious lung diseases

show abstract

Section: Acute Infectious Processesmentioning

confidence: 99%

PET/CT in nononcological lung diseases: current applications and future perspectives

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The results indicated the importance of FDG-PET in guiding the duration of treatment in most patients (n=8). The role of FDG-PET in monitoring therapeutic efficacy has also been described in the setting of invasive aspergillosis [53], candidal lung abscess following antifungal therapy [54], and Pneumocystis carinii pneumonia [55]. Similar promising results have been obtained in non-infectious inflammatory conditions also (discussed under each subheading).…”

Section: Therapeutic Response Monitoringmentioning

confidence: 73%

Clinical Utility of FDG–PET and PET/CT in Non-malignant Thoracic Disorders

et al. 2010

View full text Add to dashboard Cite

There have been several endeavors made to investigate the potential role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) (and tracers) and PET-computed tomography imaging in various benign disorders, particularly those related to thoracic structures. These various conditions can be broadly categorized into three groups: (a) infectious diseases (mycobacterial, fungal, bacterial infection), (b) active granulomatous disease such as sarcoidosis, and (c) other non-infectious/inflammatory conditions or proliferative disorders (e.g., radiation pneumonitis, post-lung transplant lymphoproliferative disorders, occupational pleuropulmonary complications, and post-surgical conditions), all of which can demonstrate varying degrees of FDG uptake on PET scans based upon the degree of inflammatory activity. This article reviews the current state of this very important application of FDG-PET imaging.

show abstract

“…Traditionally, gallium scintigraphy is used to diagnose and monitor PCP, which often demonstrates diffuse pulmonary uptake. Published case reports suggested that FDG PET-CT might be preferred to gallium scintigraphy for PCP diagnosis and monitoring, due to its better resolution, higher target to background uptake, faster imaging time and lower radiation dose [70,71].…”

Section: Pneumocystis Pneumoniamentioning

confidence: 99%

Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT

Liu

2011

Ann Nucl Med

View full text Add to dashboard Cite

HIV infection results in profound alterations of immunologic function that render the patient severely immunocompromised, and susceptible to malignancies and opportunistic infections. Three AIDS-defining malignancies include Kaposi's sarcoma (KS), non-Hodgkin's lymphoma (NHL) and invasive cervical cancer. In AIDS patients, KS is often aggressive and multifocal, with visceral involvement and widespread cutaneous and nodal spread; NHL is always high grade and often widely disseminated at the time of diagnosis with frequent involvement of extranodal sites; cervical cancer is invasive and has greater likelihood of progression and metastasis. Although there are very sparse systemic data available in the literature, limited studies has shown that FDG PET-CT is a valuable imaging technique in the diagnosis, staging, restaging and monitoring therapeutic response in these malignancies. In addition, a unique application of FDG PET/CT is the differentiation of cerebral lesions between lymphoma and toxoplasmosis in AIDS patients, which cannot be reliably achieved with either CT or MRI. HIV-associated opportunistic infections may involve different pathogens and multiple tissues, organs or systems. Some preliminary observations have revealed a promising role of FDG PET-CT in the diagnosis and identification of these infections such as tuberculosis, fever of unknown origin, pneumocystis pneumonia and candidiasis. However, it should be stressed that FDG PET-CT alone has no role in identifying the pathology of abnormalities. FDG PET-CT, at best, can localize the sites of abnormalities and impact on patient's management in clinical decision making.

show abstract

FDG-PET Imaging in Pneumocystis carinii Pneumonia

Cited by 29 publications

References 6 publications

PET/CT in nononcological lung diseases: current applications and future perspectives

PET/CT in nononcological lung diseases: current applications and future perspectives

Clinical Utility of FDG–PET and PET/CT in Non-malignant Thoracic Disorders

Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT

Contact Info

Product

Resources

About